NZ543014A - Method for production of 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,13alpha-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene - Google Patents
Method for production of 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,13alpha-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-eneInfo
- Publication number
- NZ543014A NZ543014A NZ543014A NZ54301404A NZ543014A NZ 543014 A NZ543014 A NZ 543014A NZ 543014 A NZ543014 A NZ 543014A NZ 54301404 A NZ54301404 A NZ 54301404A NZ 543014 A NZ543014 A NZ 543014A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- approximately
- radical
- mixture
- sulfolane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The disclosure relates to a method for the production of 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,13alpha-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene of formula (I) from 4-acetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,13alpha-dihydroxy-9-oxo-7beta-trifluoromethylsulfonyloxy-tax-11-ene by reaction with a molecular sieve in sulpholane.
Description
New Zealand Paient Spedficaiion for Paient Number 543014
543014
METHOD FOR PRODUCTION OF 4,lqp-DIACETOXY-2q-BENZOYLOXY-53,20-EPQXY-l,13a-DIHYDROXY-9-QXO-19-NORCYCLOPROPA[q]TAX-11-ENE
The present invention relates to a novel process for the preparation of taxoids of general formula:
In the general formula (I),
Ar represents an aryl radical,
R represents a hydrogen atom or an acetyl, (C3-C6) alkoxyacetyl or (C1-c4) alkyl radical,
Ri represents a benzoyl radical or an r2-O-CO- radical 15 in which R2 represents a straight or branched alkyl radical comprising 1 to 8 carbon atoms.
Preferably, Ar represents a phenyl radical optionally substituted by one or more atoms or radicals chosen 20 from halogen atoms (fluorine, chlorine, bromine or iodine) and alkyl, alkoxy, alkylthio, cyano, nitro and trifluoromethyl radicals, it being understood that the alkyl radicals and the alkyl portions of the radicals comprise 1 to 4 carbon atoms, or else Ar represents an 25 aromatic heterocyclic radical having 5 ring members and comprising one or more identical or different atoms chosen from nitrogen, oxygen or sulfur atoms.
More particularly, Ar represents a phenyl, 2- or 30 3-thienyl or 2- or 3-furyl radical.
intellectual wwpiwvtl of mi
H OCT 2005
Bjicjijypf)
543014
More particularly still, Ar represents a phenyl radical optionally substituted by a chlorine or fluorine atom or by an alkyl (methyl), alkoxy (methoxy) or 2- or 3-thienyl or 2- or 3-furyl radical.
Of even more particular advantage is the product of general formula (I) in which Ar represents a phenyl radical, Ri represents a tert-butoxycarbonyl radical and R represents an acetyl radical.
Mention may be made, among the processes known to date for preparing the compounds of formula (I), of patent EP 0 673 372, which discloses, starting from 10-deacetylbaccatin III, a process which consists, in a 15 first stage, in protecting the 10-deacetylbaccatin III in the 7 position, in a second stage, in acetylating in the 10 position, in a third stage, in deprotecting the 7 position, in a fourth stage, in carrying out a trifluoromethanesulfonylation (or triflation) in the 7 20 position, in a fifth stage, in carrying out a cyclopropylation in the 7-8 position, then, in a penultimate stage, in attaching the side chain in the 13 position and, finally, in a final stage, in deprotecting the side chain. The stage of 25 cyclopropylation in the 7-8 position is carried out in the presence either of an alkali metal halide (sodium iodide, potassium fluoride) or of an alkali metal azide (sodium azide) or of a quaternary ammonium salt or, finally, of an alkali metal phosphate.
It became apparent later, as disclosed in the patents published under the numbers WO 95/33736, WO 95/33737 and WO 96/32387, that the presence of alkali metal azide or halide (sodium iodide, potassium fluoride) was 35 not essential and that an additive such as as molecular sieves in the presence of sodium chloride was effective. The solvent used in these three patent applications was composed of a mixture of acetonitrile and of tetrahydrofuran.
543014
3
It is also known, from the paper by Johnson, Nidy, Dobrowolski, Gebhard, Quails, Wicnienski and Kelly which appeared in Tetrahedron Letters, Vol. 35, No. 43, 5 pp 7893-7896, 1994, that the 7-0-triflate could be converted to 70,8p-methanotaxane in the presence of a large excess of silica gel; the excess is 60 times the weight of the 7-O-triflate derivative, which is unusable industrially.
According to the present invention, the process disclosed in the three abovementioned patents has been improved by the use of sulfolane.
The compound of following formula (I)
o
As ho ococh.
:o
(i)
dcoc6h5
in which
Ar represents an aryl radical,
R represents a hydrogen atom or an acetyl, alkoxyacetyl or alkyl radical,
Ri represents a benzoyl radical or an R2-O-CO-
radical in which R2 represents a straight or branched alkyl radical comprising 1 to 8 carbon atoms,
is prepared by a process which consists in bringing the compound of formula (II)
543014
HO"
(ii)
OCOCH,
OCOC6H5
in which R' is a protective group for the hydroxyl functional group when R represents hydrogen in the formula (I) or one of the groups cited for R, into contact with a weak base chosen from molecular sieves, then, successively or beforehand, in coupling a precursor of the side chain and, finally, in deprotecting the optionally protected hydroxyl functional groups, which comprises carrying out the cyclopropanation reaction in sulfolane.
The present invention also relates to a process for the preparation of an intermediate of general formula (III)
HO"
t)COCeHg
(111)
in which R' has the same meaning as in the formula (II) above, by bringing the derivative of general formula (II) into contact with a molecular sieve, which is carried out in sulfolane.
In an entirely preferred way, the cyclopropylation reaction is carried out in sulfolane comprising between 2 and 5% by weight of water. The presence of water makes possible the conversion of the derivative of
543014
formula (IV) below, a by-product produced during the cyclopropanation, to the derivative of formula (V) ; the separation of the derivative of formulae (III) and of the derivative of formula (IV) is difficult, whereas 5 the separation of the derivative of formula (V) from the derivative of formula (III) is easier.
<IV) (V)
For better implementation of the invention, it is preferable to operate with an amount of water of approximately 4% by the sulfolane. The reaction temperature is in particular between 20°C and the boiling point of the reaction 15 mixture.
The addition is carried out of preferably 25 to 100% by weight of molecular sieve with respect to the substrate. As regards the reaction conditions, the 20 reaction is generally carried out between 20°C and the boiling point of the solvent for one to several hours.
According to a better process for implementing the invention, use will be made of the hydrated sulfolane 25 (approximately 4% of water by weight) as reaction solvent in the presence of 100% by weight of 4 A molecular sieve as activated powder with respect to the substrate. In this case, the reaction will be carried out at a temperature in the region of 60°C until the 30 substrate has been completely converted.
543014
The product of formula (II) in which R' represents a protective group for the hydroxyl functional group or an acetyl, alkoxyacetyl or alkyl radical can be obtained by reaction of a derivative of 5 trifluoromethanesulfonic acid, such as the anhydride or the chloride, with baccatin III or 10-deacetylbaccatin III protected on its 10 position by a protective group, such as in particular trichloroethoxycarbonyl.
Generally, the reaction of a derivative of trifluoromethanesulfonic acid is carried out in an inert organic solvent (aliphatic hydrocarbons, optionally halogenated, or aromatic hydrocarbons) in the presence of an organic base, such as a tertiary 15 aliphatic amine (triethylamine) or pyridine, at a temperature of between -50 and +20°C.
According to a better process for implementing the invention, where one of the preferred compounds of 20 formula (III) where R represents an acetyl group is prepared from the compound of formula (II) where R has the same meaning,
after reaction of the compound of formula (II) with the molecular sieve:
- the crude product is isolated by a series of treatments, such as the optional addition of a solvent, such as ethyl acetate, the removal of the insoluble materials by filtration, the concentration of the reaction medium and then the crystallization by 30 addition of solvents which induce insolubility, such as those chosen in particular from water or toluene,
then either the crude product is purified by recrystallization from a solvent or solvent mixture, such as methanol, methanol as a mixture with 35 diisopropyl ether or toluene, sulfolane as a mixture with toluene, or methylene chloride as a mixture with diisopropyl ether, or ethyl acetate as a mixture with diisopropyl ether,
543014
7
or the crude product is purified by chromatography on silica gel, elution being carried out with methylene chloride as a mixture with ethyl acetate, methanol or acetonitrile.
Preferably, the medium will be treated by addition of ethyl acetate, filtration of the molecular sieve, concentration under reduced pressure and precipitation by addition of water with seeding.
Preferably, the crude product will be purified by crystallization from an ethyl acetate/diisopropyl ether mixture with a ratio of between 50/50 v/v and 10/90 v/v and preferably equal to 25/75.
The product of formula (III) obtained is subsequently or previously coupled according to methods known to a person skilled in the art with a precursor of the side chain chosen from p-phenylisoserine protected in the 2' position, such as disclosed in patent EP 336 840, oxazolidines, such as disclosed in particular in patents EP 595 370, EP 663 906, EP 663 907, EP 663 908, EP 666 857 and EP 669 915, or p-lactams, such as disclosed in particular in the following patents EP 400 971, US 5,254,580 and US 5,466,834.
The term "comprising" as used in this specification means "consisting at least in part of". When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner.
intellectual propbh i -office of n z
2 7 NOV 2008
5430~( £
In the description in this specification reference may be made to subject matter which is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.
The following examples illustrate the present invention but should not be regarded as a limitation on the invention.
EXAMPLE 1
2.0 g of 4,10p-diacetoxy-2a-benzoyloxy-5pf20-epoxy-1,13a-dihydroxy-9-oxo-7(3- (trif luoromethylsulf onyloxy) tax-ll-ene with a purity of 92%, 2.02 g of 4 A molecular sieve as activated powder and 1.0 g of sodium chloride are charged to 14 ml of sulfolane in a 50 ml three-necked flask and the mixture is heated at 60°C for approximately 4 hours. The reaction medium is
5430 14
543014
cooled to ambient temperature and then filtered. The insoluble materials are washed in 3 times with 50 ml of ethyl acetate and the organic phases are combined. The 4,10(3-idiacetoxy-2a-benzoyloxy-5pf 20-epoxy-l, 13a-5 dihydroxy-9-oxo-19-norcyclopropa[g]tax-ll-ene (I)
solution thus obtained is quantitatively determined by HPLC with respect to a standard (1.29 g, yield of 88%).
Comparative examples with different solvents
The results are shown in the following table:
Example
Solvent
Conditions
DC
Yield
Observations
CI
AcCN/THF lOv/lv
g, reflux 3 hours
> 99%
69%
13.5% acetamido 7.7% ethylen-1
C2
DMF
0.5 g 40 - 50°C 7 hours 30
98%
70%
16.5% ethylen-2
C3
NMP
0.5 g 50°C, 3 hours
> 99%
12.6%
Decomposition
C4
Acetone
3 g reflux 2 hou r s
> 99%
.6% ethylen-1 40% 7-epi OH
OAc
HO'"
HO
OCOCH,
HO'i"
HO
OCOCH,
ACETAMIDO
OAc. o
HO"11
ETHYLEN-2 or <IV>
ETHYLEN-1 or (V)
OAc
HO"
HO
OCOCH,
OCOC6H5 7-epi OH
543014
EXAMPLE 2
60.0 g of 4,10|i-diacetoxy-2a-benzoyloxy-p, 20-epoxy-1,13a-dihydroxy-9-oxo-7p-(trifluoromethylsulfonyloxy) 5 tax-ll-ene with a purity of 89.8% by weight, 60 g of 4 Angstrom molecular sieve as activated powder and 9.6 ml of water are charged to 240 g of sulfolane in a 500 ml three-necked flask and the mixture is heated with stirring at 60°C for approximately 4 hours. The 10 reaction medium is cooled to 40°C and 200 ml of ethyl acetate are added. The suspension is filtered through a bed of Dicalite and the insoluble material is washed 4 times with 50 ml of ethyl acetate. The organic phases are combined and the 4,10p-diacetoxy-2a-benzoyloxy-15 5p,20-epoxy-l,13a-dihydroxy-9-oxo-19-norcyclopropa[g]
tax-ll-ene solution thus obtained is quantitatively determined by HPLC with respect to a standard (37.5 g, yield of 88%) . A fraction of the solution (152 g) is concentrated under a pressure of less than 15 mmHg at 20 45°C for approximately 45 minutes and the concentrate obtained (75.2 g) is stirred at 40°C. 59.2 ml of demineralized water are added over one hour to the solution and then seeding is carried out at 40°C with 100 mg of 4,10p-diacetoxy-2a-benzoyloxy-5p,20-epoxy-25 1,13a-dihydroxy-9-oxo-19-norcyclopropa[g]tax-ll-ene.
The medium is cooled to ambient temperature over 2 hours 30 minutes and then 80.3 g of demineralized water are again run in over 1 hour. The suspension is then cooled to 0-4°C over approximately 1 hour 30 minutes. 30 The product is filtered off, washed 3 times with 33 ml of demineralized water and dried under reduced pressure at 45°C for 16 hours. 12.65 g of crude product are thus obtained, which product has a purity of 70.8% by weight quantitatively determined by HPLC (yield of 83%).
12.5 g of crude product are charged to a 100 ml round-bottomed flask and are dissolved in 25 ml of methanol at 55°C. The reaction medium is cooled to 35°C and then seeded with a few mg of 4,10p-diacetoxy-2a-benzoyloxy-
543014
5p,20-epoxy-l,13a-dihydroxy-9-oxo-19-norcylcopropa[g] tax-ll-ene. The suspension is then cooled to ambient temperature and then to 0-4°C over approximately 3 hours. After filtration, the product is washed twice 5 with 5 ml of diisopropyl ether and then dried under reduced pressure at 45°C for 16 hours. 7.1 g of pure product are thus obtained, which product has a purity of 97.7% by weight quantitatively determined by HPLC (recrystallization yield of 66%).
EXAMPLES 3 to 5
Example 2 is repeated as far as the crude product, a variable amount of water being added to the sulfolane.
Example
Conditions
ETHYLEN-1
ETHYLEN-2
3
Sieve 60°C, 4 hours
3.6
.5
4
Sieve 60°C, 4 hours, 1% water
6.9
2.4
Sieve 60°C, 4 hours, 2% water
7.9
1.4
2
Sieve 60°C, 4 hours, 4% water
CO -J
0.2
The impurity named ETHYLEN-2 is difficult to separate from (III) by silica chromatography or crystallization; in contrast, the impurity named ETHYLEN-1 is easily removed by these same techniques.
EXAMPLE 6 - Purification by crystallization from methanol
58 g of 4,10p-diacetoxy-2a-benzoyloxy-p,20-epoxy-l,13a-25 dihydroxy-9-oxo-7p-(trifluoromethylsulfonyloxy)tax-ll-ene with a purity of 92%, 58 g of 4 angstrom molecular sieve as activated powder and 29 g of sodium chloride are charged to 580 ml of ethyl acetate in a 2-liter glass reactor and the mixture is heated with stirring 30 at between 55 and 65°C for approximately 46 hours. The
543014
reaction medium is cooled to ambient temperature and filtered through a bed of Clarcel and the insoluble material is washed twice with 116 ml of ethyl acetate. The organic phases are combined and the 4,10(3-5 diacetoxy-2a-benzoyloxy-5P,20-epoxy-l,13a-dihydroxy-9-oxo-19-norcyclopropa[g]tax-ll-ene solution thus obtained is washed with an aqueous sodium hydrogencarbonate solution (17.4 g in 290 ml of water) and then twice with 290 ml of water. The reaction 10 medium is concentrated to a volume of approximately 200 ml under reduced pressure at a temperature of less than 40°C and 825 ml of methanol are added. The change in solvent is carried out by distillation under reduced pressure at a temperature of less than 4Q°C with 15 addition of methanol (1145 ml in total) and then the solution is cooled to ambient temperature. Crystallization is initiated with 0.21 g of 4,10p-diacetoxy-2a-benzoyloxy-5p,20-epoxy-l,13a-dihydroxy-9-oxo-19-norcyclopropa[g]tax-ll-ene and then the 20 suspension is cooled to 0°C over approximately 1 hour 30 minutes. The suspension is filtered and the product is washed twice with 116 ml of diisopropyl ether. After drying at ambient temperature to constant weight, 25 g of product are obtained (yield of 55%), which product 25 assays at 94% by weight by HPLC quantitative determination (> 99% by area internal normalization).
EXAMPLE 7 - Purification by chromatography
4.9 g of crude 4,10p-diacetoxy-2a-benzoyloxy-5p,20-epoxy-l , 13a-dihydroxy-9-oxo-19-norcyclopropa[g]tax-ll-ene with an HPLC purity of 93.9% (internal normalization of the areas) and assaying at 65.5% by weight are purified by chromatography with 250 g of 35 silica gel, elution being carried out with a mixture of methylene chloride and ethyl acetate (v/v: 75/25). The fractions comprising the product are combined and concentrated under reduced pressure. The solution
Claims (12)
1. A process for the preparation of the compound of formula (I) in which Ar represents an aryl radical, R represents a hydrogen atom or an acetyl, alkoxyacetyl or alkyl radical, Ri represents a benzoyl radical or an R2-0-CO-radical in which R2 represents a straight or branched alkyl radical comprising 1 to 8 carbon atoms, by a process which consists in bringing the compound of formula (II) R'-O O 0-S02-CF3 HO' OCOCH, OCOC6H5 (H) in which R' is a protective group for the hydroxyl functional group when R represents hydrogen in the 543014 - 14 - formula (I) or one of the groups cited for R, into contact with a weak base chosen from molecular sieves, then, successively or beforehand, in coupling a precursor of the side chain and, finally, in deprotecting the optionally protected hydroxyl functional groups, which comprises carrying out the cyclopropanation reaction in sulfolane.
2. The process as claimed in claim 1, wherein R is an acetyl radical, Ri is a tert-butoxycarbonyl radical and Ar is a phenyl radical.
3. The process as claimed in claim 1, wherein the reaction is carried out in the presence of 4 A molecular sieve as activated powder.
4. The process as claimed in claim 1 or 3, wherein use is made of a ratio by weight of the molecular sieve to the compound of formula (II) of approximately 100% by weight.
5. The process as claimed in any one of claims 1 to 4, wherein the sulfolane comprises 2 to 5% by weight of water.
6. The process as claimed in claim 5, wherein the sulfolane comprises approximately 4% of water.
7. The process as claimed in any one of claims 1 to 6, wherein the reaction temperature is between 20°C and the boiling point of the solvent.
8. The process as claimed in claim 6, wherein the reaction temperature is approximately 60°C.
9. The process as claimed in claim 1, wherein the crude product is isolated by addition of ethyl acetate to the reaction medium, filtration of the intellectual property office of n.2. 19 OCT 2006 543014 15
10.
11.
12. molecular sieve, concentration of the reaction medium and then crystallization by addition of water. The process as claimed in claim 9, wherein, after isolation, the crude product is purified by recrystallization from a solvent or solvent mixture chosen from methanol, methanol as a mixture with diisopropyl ether, methanol as a mixture with toluene, sulfolane as a mixture with toluene, methylene chloride as a mixture with diisopropyl ether, or ethyl acetate as a mixture with diisopropyl ether. The process as claimed in claim 10, wherein the crude product is purified with a mixture of ethyl acetate and isopropyl ether according to a ratio of approximately 25/75 v/v. The process as claimed in claim 1, wherein the precursor of the side chain is chosen by derivatives of (3-phenylisoserine protected in the 2' position, oxazolidines or (3-lactams. A process for the preparation of an intermediate of general formula (III) O HO' HO OCOCH, fO (III) 3 0COC6H5 in which R' has the same meaning as in the formula (II) of claim 1, 543014 14 . 15. 16. - 16 - by bringing a derivative of general formula (II) into contact with a molecular sieve, which is carried out in sulfolane. A process as defined in claim 1 substantially as herein described with reference to any example thereof. A process as defined in claim 13 substantially as herein described with reference to any example thereof. A compound of formula (I) as defined in claim 1, when prepared by a process as defined in claim 1 or claim 14. An intermediate of general formula (III) as defined in claim 13, when prepared by a process of claim 13 or claim 15. HO"- OCOCH3 (10 HO OCOC6H5 MTELLECTUAL mOPERTvl office of n.z. 1 2 7 NOV 2008
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0304613A FR2853651B1 (en) | 2003-04-14 | 2003-04-14 | PROCESS FOR THE PREPARATION OF 4,10 BETA-DIACETOXY-2 ALPHA-BENZOYLOXY-5 BETA, 20-EPOXY-1, 13 ALPHA-DIHYDROXY-9-OXO-19-NORCYCLOPROPA [G] TAX-11-ENE |
PCT/FR2004/000901 WO2004092151A1 (en) | 2003-04-14 | 2004-04-13 | METHOD FOR PRODUCTION OF 4,10β-DIACETOXY-2$G(A)-BENZOYLOXY-5$G(B),20-EPOXY-1,13$G(A)-DIHYDROXY-9-OXO-19-NORCYCLOPROPA[G]TAX-11-ENE |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ543014A true NZ543014A (en) | 2008-12-24 |
Family
ID=33041834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ543014A NZ543014A (en) | 2003-04-14 | 2004-04-13 | Method for production of 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,13alpha-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1615902B1 (en) |
JP (1) | JP4664903B2 (en) |
KR (1) | KR101117512B1 (en) |
CN (1) | CN1317271C (en) |
AR (1) | AR043986A1 (en) |
AT (1) | ATE386733T1 (en) |
AU (1) | AU2004230302B8 (en) |
BR (1) | BRPI0409332A (en) |
CA (1) | CA2522482C (en) |
CO (1) | CO5700730A2 (en) |
CY (1) | CY1110375T1 (en) |
DE (1) | DE602004011917T2 (en) |
DK (1) | DK1615902T3 (en) |
ES (1) | ES2302008T3 (en) |
FR (1) | FR2853651B1 (en) |
HK (1) | HK1088306A1 (en) |
IL (1) | IL171318A (en) |
MX (1) | MXPA05010990A (en) |
NO (1) | NO331813B1 (en) |
NZ (1) | NZ543014A (en) |
PL (1) | PL1615902T3 (en) |
PT (1) | PT1615902E (en) |
RU (1) | RU2341520C2 (en) |
TW (1) | TWI360545B (en) |
WO (1) | WO2004092151A1 (en) |
ZA (1) | ZA200508209B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791279B2 (en) * | 2010-12-13 | 2014-07-29 | Yung Shin Pharm. Ind. Co., Ltd. | Process for preparing taxoids from baccatin derivatives using lewis acid catalyst |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5814658A (en) * | 1992-12-09 | 1998-09-29 | Rhone-Poulenc Rorer S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
IL127597A (en) * | 1994-01-28 | 2003-07-31 | Upjohn Co | Iso-taxol analogs |
FR2721023B1 (en) * | 1994-06-09 | 1996-07-12 | Rhone Poulenc Rorer Sa | New Taxoids, their preparation and the pharmaceutical compositions containing them. |
FR2726272B1 (en) * | 1994-10-26 | 1996-12-06 | Rhone Poulenc Rorer Sa | NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2732968B1 (en) * | 1995-04-14 | 1997-05-16 | Rhone Poulenc Rorer Sa | NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
-
2003
- 2003-04-14 FR FR0304613A patent/FR2853651B1/en not_active Expired - Fee Related
-
2004
- 2004-04-06 AR ARP040101161A patent/AR043986A1/en unknown
- 2004-04-13 CA CA2522482A patent/CA2522482C/en not_active Expired - Fee Related
- 2004-04-13 PL PL04742484T patent/PL1615902T3/en unknown
- 2004-04-13 PT PT04742484T patent/PT1615902E/en unknown
- 2004-04-13 RU RU2005135137/04A patent/RU2341520C2/en not_active IP Right Cessation
- 2004-04-13 DK DK04742484T patent/DK1615902T3/en active
- 2004-04-13 AU AU2004230302A patent/AU2004230302B8/en not_active Ceased
- 2004-04-13 WO PCT/FR2004/000901 patent/WO2004092151A1/en active IP Right Grant
- 2004-04-13 AT AT04742484T patent/ATE386733T1/en active
- 2004-04-13 CN CNB2004800097622A patent/CN1317271C/en not_active Expired - Fee Related
- 2004-04-13 EP EP04742484A patent/EP1615902B1/en not_active Expired - Lifetime
- 2004-04-13 KR KR1020057019582A patent/KR101117512B1/en not_active IP Right Cessation
- 2004-04-13 ES ES04742484T patent/ES2302008T3/en not_active Expired - Lifetime
- 2004-04-13 TW TW093110164A patent/TWI360545B/en not_active IP Right Cessation
- 2004-04-13 NZ NZ543014A patent/NZ543014A/en not_active IP Right Cessation
- 2004-04-13 DE DE602004011917T patent/DE602004011917T2/en not_active Expired - Lifetime
- 2004-04-13 MX MXPA05010990A patent/MXPA05010990A/en active IP Right Grant
- 2004-04-13 JP JP2006505793A patent/JP4664903B2/en not_active Expired - Fee Related
- 2004-04-13 BR BRPI0409332-1A patent/BRPI0409332A/en not_active IP Right Cessation
-
2005
- 2005-10-09 IL IL171318A patent/IL171318A/en not_active IP Right Cessation
- 2005-10-11 ZA ZA200508209A patent/ZA200508209B/en unknown
- 2005-10-12 CO CO05104379A patent/CO5700730A2/en not_active Application Discontinuation
- 2005-11-11 NO NO20055332A patent/NO331813B1/en not_active IP Right Cessation
-
2006
- 2006-08-01 HK HK06108520A patent/HK1088306A1/en not_active IP Right Cessation
-
2008
- 2008-05-12 CY CY20081100493T patent/CY1110375T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1215708A (en) | New process for the synthesis of pyrido-imidazo- rifamycins | |
GB2137992A (en) | New 3,4-dihydro isoquinoline, 3,4-dihydronaphthalene derivatives and the process for preparing the same | |
NO313141B1 (en) | Esters of baccatin-III and 10-desacetyl-baccatin-III, their preparation and intermediates | |
AU2005291357A1 (en) | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel | |
NZ528401A (en) | New process for the industrial synthesis of tetraesters of 5-[bis-(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates | |
JP2006501305A (en) | Cefdinir intermediate salt | |
CA3100162A1 (en) | Process for the preparation of apalutamide | |
CA3129136A1 (en) | Method of preparing a don prodrug from l-pyroglutamic acid | |
WO2015068159A2 (en) | Process for the preparation of n-iodoamides | |
JP5209426B2 (en) | Method for producing 1,2,4-oxadiazole derivative | |
NZ543014A (en) | Method for production of 4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1,13alpha-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene | |
US6956124B2 (en) | Process for the preparation of 4,10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1,13α-dihydroxy-9-oxo-19-norcyclopropa[g]tax-11-ene | |
CN110950836B (en) | Preparation method of benzodithiol heterocyclic alkene skeleton compound | |
CN108047179B (en) | Fullerene dihydrofuran compound and preparation method thereof | |
KR100286157B1 (en) | Process for preparing dioxoazabicyclohexanes | |
JP3171400B2 (en) | Hydroxycarbonyl derivative and method for producing the same | |
Yamazaki et al. | C‐5 functionalization of trisubstituted imidazoles with azodicarbonyl compounds | |
KR20010029475A (en) | Process to Prepare Pharmaceutical Compounds | |
GB2248060A (en) | Process for preparing 1-[(2S)-3-mercapto-2-methyl-1-oxopropyl]-L-proline | |
JPH04103589A (en) | 3'-alkyl or aryl silyloxybenzoxazinorifamycin derivative | |
JP2002138086A (en) | Manufacturing method of alkyloxyaminofuranone derivative | |
JPH08311006A (en) | Production of fluorenylidene aniline derivative | |
IE62681B1 (en) | Process for the preparation of 2-(2-bromo-2-nitroethenyl) furan | |
JP2003292483A (en) | Method for producing alicyclic bismaleimide compound | |
PL145341B1 (en) | Method of obtaining derivatives of n-acyl-l-proline |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
LAPS | Patent lapsed |